| Project/Area Number |
24592527
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Saitama Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
EGUCHI Hidetaka 埼玉医科大学, 医学部, 准教授 (00260232)
WADA Satoshi 埼玉医科大学, 医学部, 助教 (80438837)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 卵巣癌 / マイクロRNA / 遺伝子発現 / バイオマーカー / 癌 / 遺伝子 / 発現制御 |
|---|
| Outline of Final Research Achievements |
We investigated the biomarker of ovarian cancer using the samples and clinical information of a phase II study of dose-dense Paclitaxel combined with intraperitoneal chemotherapy of Carboplatin (ddTCip). We performed miRNA array, and analyzed miRNA expression and its relationship with clinical information. We found decreased levels of miR-100, miR-126, and miR-145 expression in patients with PR or CR, which suggests potential predictive marker for ddTCip therapy. In addition, we observed increased levels of miR-142-3p and miR-28-5p expression in platinum resistant ovarian cancer patients. Confirmation and validation is warranted in on-foing phase III trial of ddTCip therapy (iPocc trial).
|
